The DOI matches its OpenAlex record.
PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
Open accessAbstract
Background: The PRISMS study demonstrated significant clinical and MRI benefit at 2 years for interferon-beta -1a, 22 and 44 meg thrice weekly (tiw), compared with placebo in relapsing-remitting MS. Years 3 and 4 extension study results are reported. Methods: Patients initially receiving placebo were randomized to blinded interferon-beta -1a, 22 or 44 meg tiw (n = 172; crossover group); others continued blinded treatment with their originally assigned dose, 22 meg (Rx22 group) or 44 meg (Rx44 group) tiw (n = 167 per group). Patients had 3- to 6-month clinical and annual MRI assessments. Results: Relapse rates for 4 years were 1.02 (crossover), 0.80 (Rx22, p < 0.001), and 0.72 (Rx44, p < 0.001); the dose effect approached significance (p = 0.069; risk ratio, 0.88; 95% CI, 0.76-1.01). Crossover groups showed reductions in relapse count, MRI activity, and lesion-burden accumulation with interferon-p-la compared with their placebo period (p < 0.001 both doses). Time to sustained disability progression was prolonged by 18 months in the Rx44 group compared with the crossover group (p = 0.047). Rx22 and Rx44 reduced new T2 lesion number and lesion burden compared with crossover (p < 0.001); Rx44 was superior to Rx22 on several clinical and MRI outcomes. Persistent neutralizing antibodies developed in 14.3% (Rx44) and 23.7% (Rx22) of patients and were associated with reduced efficacy. Conclusions: Clinical and MRI benefit continued for both doses up to 4 years, with evidence of dose response. Outcomes were consistently better for patients treated for 4 years than for patients in crossover groups. Efficacy decreased with neutralizing antibody formation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Self-citationTreatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Self-citationRandomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial
Panitch, H., Goodin, D. S., Francis, G., Chang, P., Coyle, P. K., O’Connor, P., Monaghan, E., Li, D., & Weinshenker, B. (2002) · Neurology · doi:10.1212/01.wnl.0000034080.43681.da · Cited by 635
Self-citationKappos, L., Freedman, M. S., Polman, C. H., Edan, G., Hartung, H.-P., Miller, D. H., Montalbán, X., Barkhof, F., Radü, E.-W., Bauer, L., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61194-5 · Cited by 502
Self-citation(1973) · BMJ · doi:10.1136/bmj.2.5863.432 · Cited by 488
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
He, A., Merkel, B., Brown, J. W. L., Zhovits Ryerson, L., Kister, I., Malpas, C. B., Sharmin, S., Horakova, D., Kubala Havrdova, E., Spelman, T., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30067-3 · Cited by 465
Brain health: time matters in multiple sclerosis
Giovannoni, G., Butzkueven, H., Dhib-Jalbut, S., Hobart, J., Kobelt, G., Pepper, G., Sormani, M. P., Thalheim, C., Traboulsee, A., & Vollmer, T. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.07.003 · Cited by 458
Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions
Banwell, B., Ghezzi, A., Bar-Or, A., Mikaeloff, Y., & Tardieu, M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70242-9 · Cited by 394
Sorensen, P. S., Ross, C., Clemmesen, K. M., Bendtzen, K., Frederiksen, J. L., Jensen, K., Kristensen, O., Petersen, T., Rasmussen, S., Ravnborg, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14541-2 · Cited by 383
Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
Salzer, J., Svenningsson, R., Alping, P., Novakova, L., Björck, A., Fink, K., Islam-Jakobsson, P., Malmeström, C., Axelsson, M., Vågberg, M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003331 · Cited by 354
Disease‐modifying treatments for multiple sclerosis – a review of approved medications
Torkildsen, Ø., Myhr, K. ‐., & Bø, L. (2016) · European Journal of Neurology · doi:10.1111/ene.12883 · Cited by 280
New natural history of interferon‐β–treated relapsing multiple sclerosis
Trojano, M., Pellegrini, F., Fuiani, A., Paolicelli, D., Zipoli, V., Zimatore, G. B., Di Monte, E., Portaccio, E., Lepore, V., Livrea, P., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21102 · Cited by 270
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
Kappos, L., Traboulsee, A., Constantinescu, C., Erälinna, J. P., Forrestal, F., Jongen, P., Pollard, J., Sandberg-Wollheim, M., Sindic, C., Stubinski, B., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237994.95410.ce · Cited by 257
Self-citationBG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety
Fox, R. J., Kita, M., Cohan, S. L., Henson, L. J., Zambrano, J., Scannevin, R. H., O'Gorman, J., Novas, M., Dawson, K. T., & Phillips, J. T. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.849236 · Cited by 124
Changes in the ascertainment of multiple sclerosis
Marrie, R. A., Cutter, G., Tyry, T., Hadjimichael, O., Campagnolo, D., & Vollmer, T. (2005) · Neurology · doi:10.1212/01.wnl.0000178891.20579.64 · Cited by 93
An Italian family affected by Nasu-Hakola disease with a novel genetic mutation in the TREM2 gene
Soragna, D. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.6.825-a · Cited by 75
Zhan, J., Yakimov, V., Rühling, S., Fischbach, F., Nikolova, E., Joost, S., Kaddatz, H., Greiner, T., Frenz, J., Holzmann, C., et al. (2019) · Cells · doi:10.3390/cells8111439 · Cited by 25
Link of the mechanisms of action of glatiramer acetate to its long-term clinical data.
Moreau, T. (2009) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(09)70005-x · Cited by 2
Metadata
- Authors
- Francis, G., Hughes, R. A., King, J. O., Mitchell, P. I., Joubert, J.-M., McLeod, J., Parker, G., Pollard, J. D., Sindic, C., Duprez, T. P. J., Medaer, R., Broeckx, J. L., Vanroose, E., Carton, H., Wilms, G., Rice, G. P. A., Ebers, G. C., Lee, D. H., Freedman, M., Nelson, R., Rabinovitch, H., Christie, S., Avruch, L., Oger, J., Paty, D. W., Li, D., Wikstrom, J., Olm., S., Panelius, M., Erälinna, J.-P., Sonninen, P. H., Rieckmann, P., Hahn, D. W., Flachenecker, P., Hartung, H., Uitdehaag, B. M. J., Bertelsmann, F. W., Barkhof, F., Hommes, O. R., Jongen, P. J., van Doorn, P. A., Tanghe, H. L. J., Sandberg‐Wollheim, M., Larsson, E., Lonntoft, M., Sallerfors, S., Kappos, L., Lienert, C., Radue, E. W., Chofflon, M., Roth, S., Castillo, V., Schwieger, A. F., Rac., H., Clews, A. M., Bingham, J. B., Barnes, D., Clifton, A. G., Stoy, N. S., Bates, D., Coulthard, A., Blumhardt, L. D., Evans, S., Jaspan, T., Palace, J. A., Newsom–Davis, J., Byrne, J., Quaghebeur, G., Li, D., Zhao, G., Riddehough, A., & Rhodes, B.
- Venue
- DIAL (Catholic University of Leuven)
- Publisher
- KU Leuven
- Published
- 2001-12-31
- Volume
- 56
- Pages
- 1628-1636
- OpenAlex
- W2513768836
- Cited by
- 472
- References
- 0
- FWCI
- 27.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.